Genetic predisposition to drug-induced hepatotoxicity

Journal of Hepatology, Supplement

Volumn 26, Issue 2, 1997, Pages 12-21

  Larrey, Dominique ^a   Pageaux, Georges Philippe ^a  

^a HÔPITAL SAINT ELOI   (France)

Author keywords

Drugs; Hepatotoxicity; Pharmacogenetics

Indexed keywords

AMINEPTINE; CAFFEINE; CARBAMAZEPINE; CHLORPROMAZINE; CLOMETACIN; CYTOCHROME P450; DAPSONE; DEBRISOQUINE; DEXTROMETHORPHAN; DICLOFENAC; DIHYDRALAZINE; HALOTHANE; ISONIAZID; PARACETAMOL; PERHEXILINE; PHENOBARBITAL; PHENYTOIN; SULFANILAMIDE;

CONFERENCE PAPER; ENZYME ACTIVITY; GENETIC PREDISPOSITION; HUMAN; LIVER TOXICITY; PHARMACOGENETICS; PRIORITY JOURNAL;

EID: 0031005383     PISSN: 01695185     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0168-8278(97)80492-8     Document Type: Conference Paper

References (74)

1. Pessayre D, Larrey D. Acute and chronic drug-induced hepatitis. Clin Gastroenterol 1988; 2: 385-422.
2. Stricker BHCH. Drug-induced Hepatic Injury, 2nd edn. Amsterdam: Elsevier, 1992.
3. Farrell GC. Drug-induced Liver Disease. London: Churchill Livingstone, 1994.
4. Pessayre D. Mécanisme des hépatites médicamenteuses. Une conséquence de la superposition de deux systèmes xénophobes. Gastroenterol Clin Biol 1995; 19: B47-B56.
5. Pessayre D, Larrey D. Drug-induced liver injury. In: Mclntyre N, Benhamou JP, Bircher J, Rizetto M, Rodes J, eds. Oxford Textbook of Clinical Hepatology, Vol. 2. Oxford: Oxford University Press, 1991: 875-902.
6. Miguet JP, Vuitton D, Pessayre D, Allemand H, Metreau JM, Poupon R, Capron JP, Blanc F. Jaundice from troleandomycin and oral contraceptives. Ann Intern Med 1980; 92: 434.
7. Pessayre D, Larrey D, Vitaux J, Breil P, Belghiti J, Benhamou JP. Formation of an inactive cytochrome P-450 Fe (Il)-metabolite complex after administration of troleandomycin in humans. Biochem Pharmacol 1982; 31: 1699-704.
8. Fisher D, Labbe G, Berson A, Tinel M, Loeper J, Larrey D, Pessayre D. Inhibition of rat liver estrogen 2/4-hydroxylase activity by troleandomycin: comparison with erythromycin and ro.xithromycin. J Pharmacol ExpTher 1990; 254:1120-7.
9. Pessayre D, Bentata M, Degott C, Nouel O, Miguet JP, Rueff B, Benhamou JP. Isoniazid-rifampin fulminant hepatitis. A possible consequence of the enhancement of isoniazid hepatotoxicity by enzyme induction. Gastroenterology 1977; 72: 284-9.
10. Pessayre D, Dolder A, Artigou JY, Wandscheer JC, Descatoire V, Degott C, Benhamou JP. Effect of fasting on metabolite-mediated hepatotoxicity in the rat. Gastroenterology 1979; 77: 264-71.
11. Larrey D, Lettéron P, Foliot A, Descatoire V, Degott C, Genève J, Tinel M, Pessayre D. Effects of pregnancy on the toxicity and metabolism of acetaminophen in mice. J Pharmacol Exp Ther 1986; 237: 283-91.
12. Spielberg SP. In vitro assessment of pharmacogenetic susceptibility to toxic drug metabolites in humans. Fed Proc 1984; 43: 2308-13.
13. Gonzalez FJ, Idle JR. Pharmacogenetic phenotyping and genotyping. Present status and future potential. Clin Pharmacokinet 1994; 26: 59-70.
14. Nelson DR, Kamataki T, Waxman DL, Guengerich FP, Estabrook RW, Feyereisen FJ, Gonzalez FJ, Coon MJ, Gunsalus 1C, Gotoh O, Okuda K, Nebert DW. The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol 1993; 12: 1-51.
15. Maghoub A, Idle JR, Dring LG, Lancaster R, Smith RL. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977; ii: 84-6.
16. Larrey D, Amouyal G, Tinel M, Lettéron P, Berson A, Labbe G, Pessayre D. Polymorphism of dextromethorphan oxidation in a French population. Br J Clin Pharmacol 1987; 24: 676-9.
17. Eichelbaum M, Gross AS. The genetic polymorphisms of debrisoquine/sparteine metabolism - Clinical aspects. Pharmacol Ther 1990; 46: 377-94.
18. Alvan G, Bechtel B, Iselius L, Gundert-Remy U. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 1990; 39: 533-7.
19. Brosen K, Gram LF. Clinical significance of the sparteine/debrisoquine oxidation polymorphism. Eur J Clin Pharmacol 1989; 36: 537-517.
20. Morgan MY, Reshef R, Shah RR, Oates NS, Smith RL, Sherlock S. Impaired oxidation of debrisoquine in patients perhexiline liver injury. Gut 1984; 25: 1057-64.
21. Larrey D, Babany G, Tinel M, Fréneaux E, Amouyal G, Habersetzer F, Lettéron P, Pessayre D. Effect of liver diseases on dextromethorphan oxidation capacity and phenotype. Study in 107 patients. Br J Clin Pharmacol 1989; 28: 297-304.
22. Shah RR, Oates NS, Idle JR, Smith RL, Lockhart JDF. Impaired oxidation of debrisoquine in patients with perhexiline neuropathy. Br Med J 1982; 284: 295-9.
23. Watson RGP, Olomu A, Clements D, Waring RH, Mitchell S, Elias E. A proposed mechanism for chlorpromazine jaundice - defective hepatic sulphoxidation combined with rapid hydroxylation. J Hepatol 1988; 7: 72-8.
24. Larrey D, Tinel M, Amouyal G, Fréneaux E, Berson A, Fouin-Fortunet H, Babany G, Lettéron P, Iglicki F, Slama JL, Habersetzer F, Pessayre D, Benhamou JR Genetically determined oxidation polymorphism and drug hepatotoxicity. Study of 51 patients. J Hepatol 1989; 8: 158-64.
25. Larrey D, Berson A, Habersetzer F, Tinel M, Castot A, Babany G, Lettéron P, Fréneaux E, Loeper J, Dansette P, Pessayre D. Genetic predisposition to drug hepatotoxicity. Role in hepatitis caused by amineptine, a tricyclic antidepressant. Hepatology 1989; 10: 168-73.
26. Ranek L, Dalhoff K, Enghusen Poulsen H, Brosen K, Flachs H; Loft S, Wantzin P. Drug metabolism and genetic polymorphism in subjects with previous halothane hepatitis. Scand J Gastroenterol 1993; 28: 677-80.
27. Skoda RC, Gonzalez FJ, Demierre A, Meyer UA. Two mutant alleles of the human cytochrome P-450dbl gene (P450 2D1) associated with genetically deficient metabolism of debrisoquine and other drugs. Proc Natl Acad Sci 1988; 85: 5240-3.
28. Gonzalez FJ, Meyer UA. Molecular genetics of the debrisoquine/sparteine polymorphism. Clin Pharmacol Ther 1991; 50: 233-8.
29. Wedlund PJ, Aslanian WS, Me Allister CB, Wilkinson GR. Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism. Clin Pharmacol Ther 1984; 36: 773-80.
30. Kupfer A, Preisig R. Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. Eur J Clin Pharmac'ol 1984; 26: 753-9.
31. Wilkinson GR, Guengerich FP, Branch R A. Genetic polymorphism of S-mephenytoin hydroxylation. Pharmacol Ther 1989; 43: 53-76.
32. Horsmans Y, Lannes D, Pessayre D, Larrey D. Possible association between poor metabolism of mephenytoin and hepatotoxicity caused by AtriumR, a fixed combination preparation containing phénobarbital, febarbamate and difebarbamate. J Hepatol 1994; 21: 1075-9.
33. Goldstein JA, Faletto MB, Romkes-Sparks M, Sullivan T, Kitareewan S, Raucy JL, Lasker JM, Ghanayem BI. Evidence that CYP C19 is the major (S)-mephenytoïn 4-hydroxylase in humans. Biochemistry 1994; 33: 1743-52.
34. de Morals SMF, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994; 269: 15419-22.
35. de Morais SMF, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of S-mephenytoin metabolism in Japanese. 6th North American ISSX Meeting, Raleigh, NC, USA (Oct 23-27, 1994).
36. Evans DAP, Manley KA, Me Kusick VA. Genetic control of isoniazid metabolism in man. Br Med J 1960; 2: 485-91.
37. Weber WW, Hein DW. N-acetylation pharmacogenetics. Pharmacol Rev 1985; 37: 25-79.
38. Shear NH, Spielberg SP, Grant DM, Tang BK, Kalow W. Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity. Ann Intern Med 1986; 105: 179-84.
39. Rieder MJ, Shear NH, Kanee A, Tang BK, Spielberg SP. Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions. Clin Pharmacol Ther 1991; 49: 13-7.
40. Wolkenstein P, Carrière V, Charue D, Bastuji-Garin S, Revuz J, Roujeau JC, Beaune P, Bagot M. A slow acetylator genotype is a risk factor for sulphonamide-induced toxic epidermal necrolysis and Stevens-Johnson syndrome. Pharmacogenetics 1995; 5: 255-8.
41. Bourdi M, Tinel M, Beaume P, Pessayre D. Interactions of dihydralazine with cytochromes P-450 1A: a possible explanation for the appearance of anti-P-450 1A2 autoantibodies. Mol Pharmacol 1994; 45: 1287-95.
42. Cribb AE, Nakamura H, Grant DM, Miller MA, Spielberg SP. Role of polymorphic and monomorphic human arylamine N-acetyl-transferases in determining sulfamethoxazole metabolism. Biochem Pharmacol 1993; 45: 1277-82.
43. Tang BK, Kadar D, Kalow W. An alternative test for acetylator phenotyping with caffeine. Clin Pharmacol Ther 1987; 42: 509-13.
44. Philip PA, Roberts MS, Rogers HJ. A rapid method for determination of acetylation phenotype using dapsone. Br J Clin Pharmacol 1984; 17: 465-9.
45. Blum M, Demierre A, Grant DM, Heim M, Meyer UA. Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proc Natl Acad Sci 1991; 88: 5237-41.
46. Vatsis KI, Martell KJ, Weber WW. Diverse point mutation in the human gene for polymorphic N-acetyltransferase. Proc Natl Acad Sci 1991; 88: 6333-7.
47. Hickman D, Sim E. N-acetyltransferase polymorphism. Comparison of phenotype and genotype in humans. Biochem Pharmacol 1991; 42: 1007-14.
48. Grant DM. Molecular genetics of the N-acetyltransferases. Pharmacogenetics 1993; 3: 45-50.
49. Lin HJ, Han CY, Lin BK, Hardy S. Ethnic distribution of slow acetylator mutations in the polymorphic N-acetyltransferase (NAT2) gene. Pharmacogenetics 1994; 4: 125-34.
50. Mitchell SC, Waring RH, Haley CS, Smith RL, Idle JR. Genetic aspects of polymodally distributed sulphoxidation in man. Br J Clin Pharmacol 1984; 18: 507-21.
51. Mitchell SC, Waring RH. The deficiency of sulphoxidation of S-carboxymethylcysteine. Pharmacol Ther 1989; 43: 237-49.
52. Emery P, Panayi GS, Huston G, Mitchell SC, Waring RH. D-penicillamine-induced toxicity in rheumatoid arthritis: the role of sulphoxidation status and HLA-DR3. J Rheumatol 1984; 4: 626-32. '
53. Olomu AB, Vickers CR, Waring RH, Clements D, Babbs C, Warnes TW, Elias E. High incidence of poor sulfoxidation in patients with primary biliary cirrhosis. N Engl J Med 1988; 318: 1089-92.
54. Hofmann U, Eichelbaum M, Seefried S, Meese CO. Identification of thiodiglycolic acid, thiodiglycolic acid sulfoxide, and (3-carboxymethylthio)lactic acid as major human biotransformation products of S-carboxymethyl-L-cysteine. Drug Metab Dispos 1991; 19: 222-6.
55. Richman PG, Meister A. Regulation of gamma-glutamyl-cysteine synthetase by nonallosteric feedback inhibition by glutathione. J Biol Chem 1975; 250: 1422-6.
56. Spielberg SP, Garrick MD, Corash LM, Butler JB, Tietze F, Rogers L, Schulman JD. Biochemical heterogeneity in glutathione synthetase deficiency. J Clin Invest 1977; 60: 1417-20.
57. Spielberg SP, Gordon GB. Glutathione synthetase-deficient lymphocytes and acetaminophen toxicity. Clin Pharmacol Ther 1981; 29: 51-5.
58. Spielberg SP, Gordon GB, Blake DA, Goldstein DA, Herlong HF. Predisposition to phenytoin hepatotoxicity assessed in vitro . N Engl J Med 1981; 305:722-7.
59. Shear NH, Spielberg SP. Anticonvulsant hypersensitivity syndrome, in vitro assessment of risk. J Clin Invest 1988; 82: 1826-32.
60. Pirmohamed M, Graham A, Roberts P, Smith D, Chadwick D, Breckenridge AM, Park BK. Carbamazepine-hypersensitivity: assessment of clinical and in vitro chemical cross-reactivity with phenytoin and oxcarbazepine. Br J Clin Pharmacol 1991; 32: 741-9.
61. Farrell G, Prendergast D, Murray M. Halothane hepatitis. Detection of a constitutional susceptibility factor. N Engl J Med 1985; 313: 1310-4..
62. Gennis MA, Vemuri R, Burns EA, Hill JV, Miller MA, Spielberg SP. Familial occurrence of hypersensitivity to phenytoin. Am J Med 1991; 91: 631-4.
63. Gaedigk A, Spielberg SP, Grant DM. Characterization of the microsomal epoxide hydrolase gene in patients with anticonvulsant adverse drug reactions. Pharmacogenetics 1994; 4: 142-53.
64. Rieder MJ, Uetrecht J, Shear NH, Cannon M, Miller M, Spielberg SP. Diagnosis of sulfonamide hypersensitivity reactions by in vitro "rechallenge" with hydroxylamine metabolites. Ann Intern Med 1989;110: 286-9.
65. Genève J, Larrey D, Lettéron P, Descatoire V, Tinel M, Amouyal G, Pessayre D. Metabolic activation of the tricyclic antidepressant amineptine. I. Cytochrome P-450-mediated in vitro covalent binding. Biochem Pharmacol 1987; 36: 323-9.
66. Genève J, Degott C, Lettéron P, Tinel M, Descatoire V, Larrey D, Amouyal G, Pessayre D. Metabolic activation of the tricyclic antidepressant amineptine. II. Protective role of glutathione against in vitro and in vivo covalent binding. Biochem Pharmacol 1987; 36: 331-7.
67. Genève J, Larrey D, Amouyal G, Belghiti J, Pessayre D. Metabolic activation of the tricyclic antidepressant amineptine by human liver cytochrome P-450. Biochem Pharmacol 1987; 36: 2421-4.
68. Avignon JP, Dorval ED, Metman EH. Hépatotoxicité des antidépresseurs: risque familial Gastroenterol Clin Biol 1984; 8: 766.
69. Rothbard JB, Gefter ML. Interactions between immunogenic peptides and MHC proteins. Annu Rev Immunol 1991; 9: 527-65.
70. Berson A, Fréneaux E, Larrey D, Lepage V, Douay C, Mallet C, Fromenty B, Benhamou JP, Pessayre D. Possible role of HLA in hepatotoxicity. An exploratory study in 71 patients with drug-induced idiosyncratic hepatitis. J Hepatol 1994; 20: 336-42.
71. Eade OE, Grice D, Krawitt EL, Trowell J, Albertini R, Festenstein H, Wright R. HLA A and B locus antigens in patients with unexplained. Hepatitis following halothane anaesthesia. Tissue Antigens 1981; 17: 428-32.
72. Otsuka S, Yamamoto M, Kasuya S, Ohtomo H, Yamamoto Y, Yoshida TO, Akaza T. HLA antigens in patients with unexplained hepatitis following halothane anesthesia. Acta Anaesthesiol Scand 1985; 29: 497-501.
73. Stricker BHC, Blok APR, Claas FHJ, Van Parys GE, Desmet VJ. Hepatic injury associated with the use of nitrofurans: a clinicopathological study of 52 reported cases. Hepatology 1988; 8: 599-606.
74. Pariente EA, Hamoud A, Goldfain D, Latrive JP, Gislon J, Cassan P, Morin T, Staub JL, Ramain JP, Bertrand JL, Denis J, Lafon J, Labayle D, Druart F, Blanchi A, Kammerer J. Hépatites àla clométacine (DupéranR). Etude rétrospective de 30 cas. Un modèle d'hépatite auto-immune médicamenteuse? Gastroenterol Clin Biol 1989; 13: 769-74.